Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Operating Leases (2019 - 2025)

Crinetics Pharmaceuticals has reported Operating Leases over the past 7 years, most recently at $48.5 million for Q4 2025.

  • Quarterly results put Operating Leases at $48.5 million for Q4 2025, up 8.91% from a year ago — trailing twelve months through Dec 2025 was $48.5 million (up 8.91% YoY), and the annual figure for FY2025 was $48.5 million, up 8.91%.
  • Operating Leases for Q4 2025 was $48.5 million at Crinetics Pharmaceuticals, down from $49.1 million in the prior quarter.
  • Over the last five years, Operating Leases for CRNX hit a ceiling of $49.1 million in Q3 2025 and a floor of $1.5 million in Q2 2023.
  • Median Operating Leases over the past 5 years was $23.6 million (2021), compared with a mean of $24.5 million.
  • Biggest five-year swings in Operating Leases: plummeted 43.24% in 2023 and later skyrocketed 3050.62% in 2024.
  • Crinetics Pharmaceuticals' Operating Leases stood at $3.1 million in 2021, then tumbled by 34.16% to $2.0 million in 2022, then skyrocketed by 2249.56% to $47.6 million in 2023, then dropped by 6.28% to $44.6 million in 2024, then grew by 8.91% to $48.5 million in 2025.
  • The last three reported values for Operating Leases were $48.5 million (Q4 2025), $49.1 million (Q3 2025), and $43.3 million (Q2 2025) per Business Quant data.